Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
AssigneeKaruna Therapeutics, Inc.
InventorsAimesther Betancourt, Bruce Rehlaender, Roch Thibert
Life of this patent
Estimating the term…
Abstract
Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
Claims18
A method of treating a disorder ameliorated by activating muscarinic receptors in a patient in need thereof, the method comprising administering between 100 mg and 125 mg xanomeline and/or a salt thereof and between 20 mg and 30 mg trospium salt to the patient twice daily;
- wherein the xanomeline and/or a salt thereof and trospium salt are administered as a pharmaceutical composition comprising a plurality of xanomeline beads having a core comprising the xanomeline or a salt thereof and optionally a coating, and a plurality of trospium beads having a core comprising the trospium salt and optionally a coating;
- and
- wherein the pharmaceutical composition is a capsule containing the plurality of xanomeline beads and the plurality of trospium beads.
A method of treating schizophrenia in a patient in need thereof, the method comprising orally administering between 100 mg and 125 mg xanomeline tartrate and between 20 mg and 30 mg trospium chloride to the patient twice daily;
- wherein the xanomeline and/or a salt thereof and trospium salt are administered as a pharmaceutical composition comprising a plurality of xanomeline beads having a core comprising the xanomeline or a salt thereof and optionally a coating, and a plurality of trospium beads having a core comprising the trospium salt and optionally a coating.
Dependencies are inferred from the claim text.